Table 3B.
Subgroup analysis according to macrovascular invasion and extrahepatic metastasis (Group A vs Group B; Group A vs Group C).
| Group A(n = 41) | Group B(n = 60) | p value | Group A(n = 41) | Group C(n = 33) | p value | |
|---|---|---|---|---|---|---|
| mRECIST | mRECIST | |||||
| Best response (n, %) | ||||||
| CR | 4 (9.8) | 4 (6.7) | 0.712 | 4 (9.8) | 1 (3.0) | 0.373 |
| PR | 26 (63.4) | 26 (43.3) | 0.047 | 26 (63.4) | 14 (42.5) | 0.072 |
| SD | 9 (21.9) | 25 (41.7) | 0.039 | 9 (21.9) | 11 (33.3) | 0.273 |
| PD | 2 (4.9) | 5 (8.3) | 0.698 | 2 (4.9) | 7 (21.2) | 0.033 |
| ORR (CR+PR) | 30 (73.2) | 30 (50.0) | 0.020 | 30 (73.2) | 15 (45.5) | 0.015 |
| DCR (CR+PR+SD) | 39 (95.1) | 55 (91.7) | 0.698 | 39 (95.1) | 26 (78.8) | 0.033 |
| Conversion rate (n, %) | 11 (26.8) | 9 (15.0) | 0.143 | 11 (26.8) | 5 (15.2) | 0.280 |
Group A: No macrovascular invasion and extrahepatic metastasis; Group B: Macrovascular invasion (no extrahepatic metastasis); Group C: Extrahepatic metastasis.
mRECIST, modified Response Evaluation Criteria in Solid Tumors; CR, complete response;PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate;DCR, disease control rate.